Edwards Lifesciences Corp. (NYSE:EW)’s share price reached a new 52-week high during mid-day trading on Friday . The company traded as high as $117.76 and last traded at $117.40, with a volume of 2,038,738 shares. The stock had previously closed at $114.95.

A number of equities analysts recently issued reports on EW shares. Zacks Investment Research lowered Edwards Lifesciences Corp. from a “hold” rating to a “sell” rating in a report on Tuesday, July 12th. Canaccord Genuity raised their price target on Edwards Lifesciences Corp. from $123.00 to $132.00 and gave the stock a “buy” rating in a report on Monday, May 23rd. Cowen and Company reissued an “outperform” rating and set a $120.00 price target (up previously from $105.00) on shares of Edwards Lifesciences Corp. in a report on Wednesday, April 27th. Piper Jaffray Cos. reaffirmed an “overweight” rating and issued a $123.00 price objective on shares of Edwards Lifesciences Corp. in a report on Wednesday, May 25th. Finally, Guggenheim assumed coverage on Edwards Lifesciences Corp. in a report on Wednesday, June 8th. They issued a “neutral” rating on the stock. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and twenty-one have assigned a buy rating to the stock. Edwards Lifesciences Corp. has an average rating of “Buy” and an average target price of $118.13.

The firm has a 50 day moving average price of $109.04 and a 200 day moving average price of $99.02. The firm has a market capitalization of $25.02 billion and a PE ratio of 48.57.

Edwards Lifesciences Corp. (NYSE:EW) last released its earnings results on Tuesday, July 26th. The medical research company reported $0.76 EPS for the quarter, beating the consensus estimate of $0.70 by $0.06. The business had revenue of $759.30 million for the quarter, compared to analyst estimates of $724.26 million. During the same period in the prior year, the company earned $0.57 earnings per share. The firm’s revenue for the quarter was up 23.1% on a year-over-year basis. Equities analysts anticipate that Edwards Lifesciences Corp. will post $2.87 earnings per share for the current year.

In related news, CEO Michael A. Mussallem sold 49,100 shares of the company’s stock in a transaction that occurred on Thursday, August 11th. The shares were sold at an average price of $114.01, for a total value of $5,597,891.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Huimin Wang sold 13,650 shares of the company’s stock in a transaction that occurred on Tuesday, July 5th. The shares were sold at an average price of $98.44, for a total transaction of $1,343,706.00. The disclosure for this sale can be found here.

Other large investors have recently modified their holdings of the company. BlackRock Advisors LLC increased its stake in shares of Edwards Lifesciences Corp. by 117.5% in the fourth quarter. BlackRock Advisors LLC now owns 1,169,922 shares of the medical research company’s stock valued at $92,400,000 after buying an additional 631,958 shares during the period. Principal Financial Group Inc. increased its stake in shares of Edwards Lifesciences Corp. by 113.0% in the fourth quarter. Principal Financial Group Inc. now owns 355,581 shares of the medical research company’s stock valued at $28,083,000 after buying an additional 188,663 shares during the period. Birch Hill Investment Advisors LLC increased its stake in shares of Edwards Lifesciences Corp. by 86.3% in the fourth quarter. Birch Hill Investment Advisors LLC now owns 299,002 shares of the medical research company’s stock valued at $23,615,000 after buying an additional 138,539 shares during the period. RS Investment Management Co. LLC increased its stake in shares of Edwards Lifesciences Corp. by 77.6% in the fourth quarter. RS Investment Management Co. LLC now owns 168,325 shares of the medical research company’s stock valued at $13,294,000 after buying an additional 73,540 shares during the period. Finally, I.G. Investment Management LTD. increased its stake in shares of Edwards Lifesciences Corp. by 740.0% in the fourth quarter. I.G. Investment Management LTD. now owns 157,833 shares of the medical research company’s stock valued at $12,466,000 after buying an additional 139,043 shares during the period.

Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company manufactures heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. It develops hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.